Real-World Data on Potent P2Y12 Inhibition in Patients with Suspected Chronic Coronary Syndrome, Referred for Coronary Angiography.

ABSTRACT:

Introduction

Potential benefit with potent platelet inhibition in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) has been discussed. The aim of this study was to compare a potent P2Y12 inhibition strategy using ticagrelor with clopidogrel in CCS patients referred for coronary angiography (CA) and PCI if feasible.

Methods

In this retrospective real-world study, patients referred for outpatient CA due to suspected CCS were included. To adjust for group differences, a propensity score reflecting the probability of being treated with ticagrelor was calculated and added to the logistic regression outcome model.

Results

In total, 1,003 patients were included in the primary analysis (577 treated with clopidogrel and 426 with

SUBMITTER: Traff E 

PROVIDER: S-EPMC9808708 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature